These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19001146)

  • 21. [Antibody therapies for melanoma].
    Kiniwa Y; Okuyama R
    Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.
    Camacho LH
    Expert Opin Investig Drugs; 2008 Mar; 17(3):371-85. PubMed ID: 18321236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
    Tarhini AA; Kirkwood JM
    Expert Opin Biol Ther; 2008 Oct; 8(10):1583-93. PubMed ID: 18774925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.
    Calabrò L; Danielli R; Sigalotti L; Maio M
    Semin Oncol; 2010 Oct; 37(5):460-7. PubMed ID: 21074061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
    Tarhini AA; Kirkwood JM
    Curr Opin Mol Ther; 2007 Oct; 9(5):505-14. PubMed ID: 17932815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 2 study of tremelimumab in patients with advanced uveal melanoma.
    Joshua AM; Monzon JG; Mihalcioiu C; Hogg D; Smylie M; Cheng T
    Melanoma Res; 2015 Aug; 25(4):342-7. PubMed ID: 26050146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
    Comin-Anduix B; Lee Y; Jalil J; Algazi A; de la Rocha P; Camacho LH; Bozon VA; Bulanhagui CA; Seja E; Villanueva A; Straatsma BR; Gualberto A; Economou JS; Glaspy JA; Gomez-Navarro J; Ribas A
    J Transl Med; 2008 May; 6():22. PubMed ID: 18452610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
    Callahan MK; Wolchok JD; Allison JP
    Semin Oncol; 2010 Oct; 37(5):473-84. PubMed ID: 21074063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ipilimumab: showing survival benefit in metastatic melanoma.
    Minchom A; Young K; Larkin J
    Future Oncol; 2011 Nov; 7(11):1255-64. PubMed ID: 22044200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab.
    Saenger Y; Magidson J; Liaw B; de Moll E; Harcharik S; Fu Y; Wassmann K; Fisher D; Kirkwood J; Oh WK; Friedlander P
    Clin Cancer Res; 2014 Jun; 20(12):3310-8. PubMed ID: 24721645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II trial of tremelimumab in patients with metastatic melanoma.
    Camacho LH; Antonia S; Sosman J; Kirkwood JM; Gajewski TF; Redman B; Pavlov D; Bulanhagui C; Bozon VA; Gomez-Navarro J; Ribas A
    J Clin Oncol; 2009 Mar; 27(7):1075-81. PubMed ID: 19139427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the CTLA4 blockade in the treatment of malignant melanoma.
    Cranmer LD; Hersh E
    Cancer Invest; 2007 Oct; 25(7):613-31. PubMed ID: 18027152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
    Straatsma BR; Nusinowitz S; Young TA; Gordon LK; Chun MW; Rosen C; Seja E; Economou JS; Glaspy JA; Bozon V; Gomez-Navarro J; Ribas A
    Am J Ophthalmol; 2007 Jun; 143(6):958-969. PubMed ID: 17434437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
    [No Abstract]   [Full Text] [Related]  

  • 35. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation.
    Wolchok JD; Saenger Y
    Oncologist; 2008; 13 Suppl 4():2-9. PubMed ID: 19001145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
    Ribas A; Comin-Anduix B; Economou JS; Donahue TR; de la Rocha P; Morris LF; Jalil J; Dissette VB; Shintaku IP; Glaspy JA; Gomez-Navarro J; Cochran AJ
    Clin Cancer Res; 2009 Jan; 15(1):390-9. PubMed ID: 19118070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
    Robert C; Mateus C
    Med Sci (Paris); 2011 Oct; 27(10):850-8. PubMed ID: 22027422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma.
    Wang E; Kang D; Bae KS; Marshall MA; Pavlov D; Parivar K
    J Clin Pharmacol; 2014 Oct; 54(10):1108-16. PubMed ID: 24737343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New drugs in melanoma: it's a whole new world.
    Eggermont AM; Robert C
    Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune modulation in melanoma and advanced cancer therapy: anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibodies.
    Esper P
    Clin J Oncol Nurs; 2009 Oct; 13(5):547-54. PubMed ID: 19793711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.